Sarepta Therapeutics, Inc. (SRPT)

Sarepta's stock experienced significant events in the past six months. In June 2025, the stock plummeted due to a second patient death linked to Elevidys, leading to the suspension of its use in non-ambulatory patients. In July 2025, a strategic restructuring included layoffs and a pipeline pivot to siRNA programs, while the FDA requested a black box warning for Elevidys due to patient deaths, resulting in a stock surge. In November 2025, SRP-5051 development was discontinued due to safety concerns, and a boxed warning was added to Elevidys' label, restricting its use to ambulatory DMD patients. Q3 2025 saw solid financial performance with $370.0 million in net product revenue and positive cash flow. Preliminary Q4 2025 results announced in January 2026 showed $369.6 million in net product revenues, with Elevidys contributing $110.4 million, but these sales missed expectations, leading to a stock price decline.

The available information does not explicitly detail demand seasonality for Sarepta Therapeutics' products. However, factors like a severe flu season and administrative delays in starting infusions were cited as reasons for limited Elevidys sales in Q1 2025, suggesting potential fluctuations related to patient health or healthcare system capacity. The underlying demand for its treatments is likely relatively stable due to the chronic nature of DMD. Significant shifts in demand are more likely to be driven by regulatory approvals, such as the expanded FDA approval of Elevidys in June 2024.

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on precision genetic medicines for rare neuromuscular disorders, particularly Duchenne muscular dystrophy (DMD). Sarepta specializes in RNA-targeted therapeutics, gene therapy, and gene editing platforms. Its commercial product portfolio for DMD includes RNA-targeted exon-skipping therapies such as EXONDYS 51, VYONDYS 53, and AMONDYS 45. Sarepta also offers ELEVIDYS, a gene therapy for DMD, which received traditional approval in June 2024 for ambulatory individuals and accelerated approval for non-ambulatory individuals aged 4 and above.

Sarepta Therapeutics is headquartered in Cambridge, Massachusetts, USA, with a strong distribution network in the United States. The company also has an international headquarters in Dublin, Ireland, and offices in Switzerland and the United Kingdom. Sarepta is expanding its global reach, particularly in Europe and Asia, and has an office in Japan.

Sarepta's brand reputation in the past year has been significantly impacted by safety concerns surrounding its gene therapy, Elevidys. The company experienced a difficult year in 2025, marked by patient deaths and a subsequent pipeline pivot. The second patient death linked to Elevidys in June 2025 and the subsequent FDA request for a black box warning for acute liver injury on the therapy's label in July 2025, which was implemented in November 2025, negatively affected its reputation. Despite these challenges, Sarepta is recognized as a leader in precision genetic medicine for rare diseases, driven by a commitment to patients and scientific innovation.

Sarepta Therapeutics' ownership is predominantly held by institutional investors, accounting for approximately 70-90% of the shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and State Street Corp. Black Bear Offshore Master Fund LP is the largest individual shareholder, holding 9.46% of the company. Insiders collectively own around 4-7% of the company's stock. Chief Operating Officer Ian Michael Estepan sold 13,187 shares in the past six months.